



Due to its expertise in organic chemistry and technological capabilities, [Shree Ganesh Remedies Limited \(SGRL\)](#), a manufacturer of specialty and fine chemicals as well as pharmaceutical intermediates that serve various therapeutic categories like oncology, anti-diabetic, and anti-histamine, is planning to invest 60 crore over the next two years. The manufacturing capacity and chemical reaction technologies have both advanced at SGRL in preparation for future growth. The commissioning of a new GMP plant located in the current facility at unit one is included in current ongoing capex growth plans. The facility will respond to the rise in demand for Key Starting Materials (KSM) and cutting-edge pharmaceutical intermediates from large pharmaceutical companies in Europe and India. The company is also in the phase of the erection for the hydrogenation plant block, which will address high-pressure reactions for pharma intermediates as well as fine chemicals.

Site Moved. Visit our New Website

We have moved this news site from this URL

to <https://www.newprojectstracker.com/capex-news> .

Visit this site for regular updates

Buy Latest Research Reports